AU2002213579A1 - Medicaments for treating dementia - Google Patents

Medicaments for treating dementia

Info

Publication number
AU2002213579A1
AU2002213579A1 AU2002213579A AU1357902A AU2002213579A1 AU 2002213579 A1 AU2002213579 A1 AU 2002213579A1 AU 2002213579 A AU2002213579 A AU 2002213579A AU 1357902 A AU1357902 A AU 1357902A AU 2002213579 A1 AU2002213579 A1 AU 2002213579A1
Authority
AU
Australia
Prior art keywords
dementia
medicaments
alpha
lipoic acid
treating dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213579A
Inventor
Harald Borbe
Klaus Hager
Marlene Kenklies
Michael Lobisch
Andreas Marahrens
Gerald Munch
Manfred Peukert
Klaus Wessel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Viatris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris GmbH and Co KG filed Critical Viatris GmbH and Co KG
Publication of AU2002213579A1 publication Critical patent/AU2002213579A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The use of alpha -lipoic acid compounds (I) is claimed for the adjuvant therapy of dementia, where (I) is selected from alpha -lipoic acid in reduced or oxidized form or its derivatives having an intact dithiolan structure in the form of enantiomers or salts, amides, esters, thioesters, ethers or metabolites. An independent claim is included for a composition containing (I) in combination with at least one anti-dementia agent (II) or at least one neurotransmission improving agent (III). - ACTIVITY : Nootropic; neuroprotective; antiparkinsonian; anti-HIV. - MECHANISM OF ACTION : Antioxidant.
AU2002213579A 2000-06-08 2001-06-07 Medicaments for treating dementia Abandoned AU2002213579A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10027968.6 2000-06-08
DE10027968A DE10027968A1 (en) 2000-06-08 2000-06-08 Adjuvant therapy of dementia using alpha-lipoic acid or derivative, is effective in combination with antidementia or neurotransmission improving agents in improving cognitive function in e.g. Alzheimer's disease patients
PCT/EP2001/006478 WO2001093865A2 (en) 2000-06-08 2001-06-07 Medicaments for treating dementia

Publications (1)

Publication Number Publication Date
AU2002213579A1 true AU2002213579A1 (en) 2001-12-17

Family

ID=7644856

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002213579A Abandoned AU2002213579A1 (en) 2000-06-08 2001-06-07 Medicaments for treating dementia

Country Status (12)

Country Link
US (1) US20040024048A1 (en)
EP (1) EP1289522B1 (en)
JP (1) JP4373087B2 (en)
AT (1) ATE295165T1 (en)
AU (1) AU2002213579A1 (en)
CA (1) CA2411568C (en)
DE (2) DE10027968A1 (en)
DK (1) DK1289522T3 (en)
ES (1) ES2242780T3 (en)
MX (1) MXPA02012182A (en)
PT (1) PT1289522E (en)
WO (1) WO2001093865A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1381373B1 (en) * 2001-04-25 2006-06-14 Cobalz Limited Medical compositions for use in the treatment or prevention of a functional vitamin b12 deficienfcy
CA2500154C (en) * 2002-09-28 2019-01-15 Boehringer Ingelheim International Gmbh Composition comprising panax ginseng and paullinia cupana extracts
WO2006042666A1 (en) * 2004-10-18 2006-04-27 Meda Pharma Gmbh & Co. Kg R-(+)-α-LIPONIC ACID FOR THE PREVENTION OF DIABETES
US8021701B1 (en) * 2005-04-13 2011-09-20 Perry Stephen C Composition to retard the onset of symptoms of alzheimer's disease
JPWO2007119578A1 (en) 2006-03-29 2009-08-27 株式会社カネカ Nervous system cell function improver
JP2008214338A (en) * 2007-02-08 2008-09-18 Shiseido Co Ltd Agent for ameliorating lowering of high-order brain function and agent for ameliorating lowering of short-term memory
CN101945653B (en) * 2008-01-02 2013-01-16 海洋生物有限公司 Compositions and methods for treating neurodegenerative diseases
CN110996987A (en) * 2017-05-30 2020-04-10 保罗·G·爱默生 Compositions and methods for modulating the hormonal cascade in stress disorders
US10799455B1 (en) 2019-11-11 2020-10-13 King Abdulaziz University Micellles containing alpha lipoic acid as a transdermal drug delivery system
KR102598904B1 (en) * 2022-12-16 2023-11-06 닥터노아바이오텍 주식회사 Composition for preventing or treating adverse event of cholinesterase inhibitors
KR20220109296A (en) * 2021-01-28 2022-08-04 닥터노아바이오텍 주식회사 Phatmaceutical composition comprising cholinesterase inhibitor and antioxidant for preventing or treating brain disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2043897T3 (en) * 1988-01-28 1994-01-01 Koeltringer Peter COMBINATION PREPARATION, ESPECIALLY FOR THE TREATMENT OF NERVOUS CELL DISEASES.
FR2653997B1 (en) * 1989-11-09 1995-01-20 Asta Pharma Ag MEDICINAL PRODUCTS CONTAINING SULSTERS OF SULFUR CARBOXYLIC ACIDS, THEIR PREPARATION AND THEIR USE FOR CONTROLLING RETROVIRUSES.
DK0530446T3 (en) * 1991-07-05 1998-09-23 Asta Medica Ag Use of sulfur-containing carboxylic acids for the control of pathophysiologically conditioned excitation disorders
DE4309217A1 (en) * 1992-01-18 1994-07-28 Margarethe Rabien Combination product of pantothenic acid or dexpanthenol + alpha -lipoic acid + vitamin E (muscular dystrophy, polyneuropathy, muscle atrophy, ataxia, new indication ( alpha -lipoic acid + pantothenic acid) Alzheimer's disease
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
DE4218572A1 (en) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistic combination of drugs containing as active ingredient alpha-lipoic acid, dihydrolipoic acid, their metabolites as well as the oxidized and reduced enantiomers of alpha-lipoic acid such as R-alpha-lipoic acid or S-alpha-lipoic acid and metabolites of alpha-lipoic acid with vitamins A, B1 -6, B12, C and E
CA2133861C (en) * 1993-10-11 2004-03-30 Peter Koltringer Preparation for the treatment of circulatory changes
DE4343592C2 (en) * 1993-12-21 1998-04-16 Asta Medica Ag Use of R - (+) - alpha-lipoic acid and its metabolites in the form of the free acid or as salts or esters or amides for the treatment of glucose metabolic disorders in the central nervous system
DE4447599C2 (en) * 1994-11-08 1998-02-26 Asta Medica Ag Use of R, S - (+/-) - alpha-lipoic acid, R - (+) - alpha-lipoic acid, S - (-) - alpha-lipoic acid in reduced or oxidized form or the metabolites and their salts, esters, amides for the treatment of hearing disorders
US5599835A (en) * 1994-11-23 1997-02-04 Fischer; Frederick B. Use of DL-lipoic acid as a medical food in the treatment of diabetes mellitus
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
AU8768098A (en) * 1997-08-04 1999-02-22 Christopher J. Berry Method of treating disease using a tocotrienol and alpha-lipoic acid r derivatives or an ester thereof
JP2002510604A (en) * 1998-04-02 2002-04-09 アビセナ グループ， インク． Composition containing a combination of a creatine compound and a second substance
CA2352144A1 (en) * 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds

Also Published As

Publication number Publication date
ATE295165T1 (en) 2005-05-15
DE10027968A1 (en) 2001-12-13
WO2001093865A2 (en) 2001-12-13
US20040024048A1 (en) 2004-02-05
JP2003535134A (en) 2003-11-25
EP1289522A2 (en) 2003-03-12
PT1289522E (en) 2005-08-31
DE50106211D1 (en) 2005-06-16
CA2411568C (en) 2009-12-22
MXPA02012182A (en) 2003-04-25
JP4373087B2 (en) 2009-11-25
DK1289522T3 (en) 2005-09-12
EP1289522B1 (en) 2005-05-11
WO2001093865A3 (en) 2002-07-25
CA2411568A1 (en) 2002-12-06
ES2242780T3 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
DK1371645T3 (en) Use of (3S, 2'R) glycopyrronium as a drug
DE69403656T2 (en) STABLE, ORAL AND ABSORBABLE THERAPEUTIC COMPOSITIONS OF NADH AND NADPH
AU617918B2 (en) 2-aminopyrimidinone derivatives
BG106681A (en) Solutions containing epinastine
AU2002213579A1 (en) Medicaments for treating dementia
TW234691B (en)
CA2386793A1 (en) New selective retinoid agonists
EP0497001A3 (en) Oxidized-type glutathione alkyl ester
WO2001014360A3 (en) Benzopyrans and benzothiopyrans as rar selective retinoid agonists
YU15002A (en) Use of alpha-lipoinic acid or derivatives thereof
AU668239B2 (en) Nonatetraenoic acid derivative
ES2147499A1 (en) Carboxylic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds
SE9601483L (en) Preparation of composition